$PRZO
ParaZero Technologies Ltd. Stock $przo

$przo Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024024822 Filed on March 21, 2024

Income Statement

Concept	2023 Q4	2023
Revenue		$620.5K
YoY Change		10.81%
Cost Of Revenue		$476.6K
YoY Change		40.18%
Gross Profit		$143.9K
YoY Change		-34.59%
Gross Profit Margin		23.19%
Selling, General & Admin		$1.961M
YoY Change		90.37%
% of Gross Profit		1362.62%
Research & Development		$636.8K
YoY Change		-0.5%
% of Gross Profit		442.54%
Depreciation & Amortization		$17.09K
YoY Change		-14.57%
% of Gross Profit		11.87%
Operating Expenses		$2.598M
YoY Change		55.54%
Operating Profit		-$2.800M
YoY Change		93.08%
Interest Expense		$152.7K
YoY Change		-19.61%
% of Operating Profit
Other Income/Expense, Net		$210.7K
YoY Change		3.8%
Pretax Income		-$3.771M
YoY Change		128.57%
Income Tax
% Of Pretax Income
Net Earnings		-$3.771M
YoY Change		128.57%
Net Earnings / Revenue		-607.79%
Basic Earnings Per Share		$0.77
Diluted Earnings Per Share		$0.77
COMMON SHARES
Basic Shares Outstanding	10.07M shares	4.891M shares
Diluted Shares Outstanding		4.891M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$7.428M
YoY Change		8153.79%
Cash & Equivalents	$7.428M		$89.81K
Short-Term Investments
Other Short-Term Assets	$651.6K	$418.1K	$179.5K
YoY Change	262.9%	19.45%
Inventory	$264.5K	$264.5K	$304.8K
Prepaid Expenses	$349.6K		$59.42K
Receivables	$22.38K	$22.38K	$184.1K
Other Receivables		$233.5K
Total Short-Term Assets	$8.367M	$8.367M	$1.049M
YoY Change	697.32%	696.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.98K	$58.11K	$41.31K
YoY Change	20.99%	-41.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$58.11K	$58.11K	$98.20K
YoY Change	-40.83%	-41.89%
TOTAL ASSETS
Total Short-Term Assets	$8.367M	$8.367M	$1.049M
Total Long-Term Assets	$58.11K	$58.11K	$98.20K
Total Assets	$8.425M	$8.425M	$1.148M
YoY Change	634.15%	632.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$0.00	$56.68K
YoY Change		13.36%
Accrued Expenses		$490.9K
YoY Change		-22.09%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$755.1K	$755.1K	$2.382M
YoY Change	-68.3%	-68.27%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change		-100.0%
Other Long-Term Liabilities		$1.565M
YoY Change		15547.7%
Total Long-Term Liabilities	$1.565M	$1.565M	$407.6K
YoY Change	283.93%	281.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$755.1K	$755.1K	$2.382M
Total Long-Term Liabilities	$1.565M	$1.565M	$407.6K
Total Liabilities	$2.320M	$2.320M	$2.790M
YoY Change	-16.84%	-16.85%
SHAREHOLDERS EQUITY
Retained Earnings			-$1.600M
YoY Change
Common Stock	$24.53M		$13.01M
YoY Change	88.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.100M	$6.105M	-$1.642M
YoY Change
Total Liabilities & Shareholders Equity	$8.425M	$8.425M	$1.148M
YoY Change	634.15%	632.6%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income		-$3.771M
YoY Change		128.57%
Depreciation, Depletion And Amortization		$17.09K
YoY Change		-14.57%
Cash From Operating Activities		-$2.938M
YoY Change		49.15%
INVESTING ACTIVITIES
Capital Expenditures		$25.76K
YoY Change		157.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$25.76K
YoY Change		157.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$10.30M
YoY Change		405.03%
NET CHANGE
Cash From Operating Activities		-$2.938M
Cash From Investing Activities		-$25.76K
Cash From Financing Activities		$10.30M
Net Change In Cash		$7.339M
YoY Change		12131.0%
FREE CASH FLOW
Cash From Operating Activities		-$2.938M
Capital Expenditures		$25.76K
Free Cash Flow		-$2.964M
YoY Change		49.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41760
CY2023	dei	Entity Registrant Name EntityRegistrantName	ParaZero Technologies Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Dov Hoz
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Kiryat Ono
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	5555626
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.02 per share
CY2023	dei	Trading Symbol TradingSymbol	PRZO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10073956	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1197
CY2023	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7428405	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89806	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22376	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	184064	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	651560	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	179541	usd
CY2022Q4	przo	Deferred Prospective Initial Public Offering Cost DeferredProspectiveInitialPublicOfferingCost	291133	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	264468	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	304823	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8366809	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	264728	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1049367	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8127	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56893	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49981	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41311	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	58108	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	98204	usd
CY2023Q4	us-gaap	Assets Assets	8424917	usd
CY2022Q4	us-gaap	Assets Assets	1147571	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	56682	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	47260	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7543	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45097	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	690861	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	774647	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1514928	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	755086	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2381932	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1564773	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7775	usd
CY2022Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	399794	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1564773	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	407569	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10073956	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10073956	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3597442	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3597442	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	56227	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21456	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24471888	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12988292	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18423057	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14651678	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6105058	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641930	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8424917	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1147571	usd
CY2023	us-gaap	Revenues Revenues	620508	usd
CY2022	us-gaap	Revenues Revenues	560118	usd
CY2021	us-gaap	Revenues Revenues	724391	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	476610	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	337565	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	464715	usd
CY2023	us-gaap	Gross Profit GrossProfit	143898	usd
CY2022	us-gaap	Gross Profit GrossProfit	222553	usd
CY2021	us-gaap	Gross Profit GrossProfit	259676	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	636801	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	640328	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	168700	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1472872	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	766711	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	474703	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	603702	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	487904	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	345925	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	389396	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2799604	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1838610	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-987429	usd
CY2023	przo	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	504976	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	277600	usd
CY2023	przo	Issuance Expenses Attributable To Derivative Warrant Liability IssuanceExpensesAttributableToDerivativeWarrantLiability	247129	usd
CY2023	us-gaap	Interest Expense InterestExpense	152745	usd
CY2022	us-gaap	Interest Expense InterestExpense	17386	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	210675	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	202958	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	372048	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3771379	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1653038	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-615381	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.71
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4891071	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3349071	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	359743	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-6000911	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-615381	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6616292	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	6423308	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	91377	usd
CY2022	przo	Stock Issue During Period Value Benefit To The Company By An Equity Holder With Respect To Funding Transactions StockIssueDuringPeriodValueBenefitToTheCompanyByAnEquityHolderWithRespectToFundingTransactions	112715	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1653038	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641930	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	490015	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2019904	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5929625	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3066656	usd
CY2023	przo	Stock Issue During Period Value Benefit To The Company By An Equity Holder With Respect To Funding Transactions StockIssueDuringPeriodValueBenefitToTheCompanyByAnEquityHolderWithRespectToFundingTransactions	12167	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3771379	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6105058	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3771379	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1653038	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-615381	usd
CY2023	us-gaap	Depreciation Depreciation	17087	usd
CY2022	us-gaap	Depreciation Depreciation	18495	usd
CY2021	us-gaap	Depreciation Depreciation	17627	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	14815	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	52286	usd
CY2023	przo	Interest Expenses With Respect To Funding From Related Party InterestExpensesWithRespectToFundingFromRelatedParty	112373	usd
CY2022	przo	Interest Expenses With Respect To Funding From Related Party InterestExpensesWithRespectToFundingFromRelatedParty	12509	usd
CY2023	przo	Change In Fair Value Of Convertible Loan ChangeInFairValueOfConvertibleLoan	504976	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	277600	usd
CY2023	przo	Issuance Expenses Attributable To Derivative Warrant Liabilities IssuanceExpensesAttributableToDerivativeWarrantLiabilities	247129	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	33360	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	12387	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	243948	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	402365	usd
CY2023	przo	Finance Expenses FinanceExpenses	583	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33024	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4876	usd
CY2023	przo	Cash Received From Interest CashReceivedFromInterest	53804	usd
CY2022	przo	Finance Expenses FinanceExpenses	4021	usd
CY2021	przo	Finance Expenses FinanceExpenses	342	usd
CY2023	przo	Increase Decrease In Trade Receivables Net IncreaseDecreaseInTradeReceivablesNet	-161689	usd
CY2022	przo	Increase Decrease In Trade Receivables Net IncreaseDecreaseInTradeReceivablesNet	176863	usd
CY2021	przo	Increase Decrease In Trade Receivables Net IncreaseDecreaseInTradeReceivablesNet	-28595	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	472020	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	96782	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-21667	usd
CY2022	przo	Increase Decrease In Deferred Prospective Initial Public Offering Cost IncreaseDecreaseInDeferredProspectiveInitialPublicOfferingCost	252041	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6995	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-34205	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6738	usd
CY2023	przo	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-48766	usd
CY2022	przo	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	48633	usd
CY2021	przo	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-49020	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	9422	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	10145	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-35764	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-45911	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-48975	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	50836	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-83785	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	404597	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-107213	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2938300	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1971635	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-985898	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25757	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9725	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5572	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25757	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9725	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5572	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	84780	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	1514928	usd
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6695957	usd
CY2023	przo	Issuance Of Ordinary Shares Prefunded Warrants And Warrants In Private Placement Net Of Issuan IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsInPrivatePlacementNetOfIssuan	4106699	usd
CY2023	przo	Proceeds From Receipt Of Loan Related Party ProceedsFromReceiptOfLoanRelatedParty	245000	usd
CY2022	przo	Proceeds From Receipt Of Loan Related Party ProceedsFromReceiptOfLoanRelatedParty	500000	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-745000	usd
CY2022	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	107994	usd
CY2021	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	940624	usd
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	30068	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10302656	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2038142	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	910556	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7338599	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	56782	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-80914	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89806	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33024	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113938	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7428405	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89806	usd
CY2022	przo	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities	97532	usd
CY2022	przo	Conversion Of The Former Parent Companys Debt Into Ordinary Shares ConversionOfTheFormerParentCompanysDebtIntoOrdinaryShares	6508089	usd
CY2023	przo	Benefit To The Company By An Equity Holder With Respect To Funding Transactions BenefitToTheCompanyByAnEquityHolderWithRespectToFundingTransactions	12167	usd
CY2022	przo	Benefit To The Company By An Equity Holder With Respect To Funding Transactions BenefitToTheCompanyByAnEquityHolderWithRespectToFundingTransactions	112715	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2019904	usd
CY2023	przo	Stock Based Compensation Included As Issuance Costs StockBasedCompensationIncludedAsIssuanceCosts	475201	usd
CY2022	przo	Stock Based Compensation Included As Issuance Costs StockBasedCompensationIncludedAsIssuanceCosts	39091	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14700000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1600000	usd
CY2022Q4	us-gaap	Secured Debt Repurchase Agreements SecuredDebtRepurchaseAgreements	1515000	usd
CY2023Q3	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	7800000	usd
CY2023Q4	przo	Number Of Warrants Issued NumberOfWarrantsIssued	3500000	shares
CY2023Q4	przo	Number Of Shares NumberOfShares	1	shares
CY2023Q4	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	5100000	usd
CY2023	przo	Cashless Exercise CashlessExercise	8257	shares
CY2023	przo	Investors Received InvestorsReceived	2876957	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0"><b>A. Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.25in">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as to disclose contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. On an ongoing basis, management evaluates its estimates, judgments and assumptions. Management bases its estimates, judgments and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Depreciation Depreciation	17087	usd
CY2022	us-gaap	Depreciation Depreciation	18495	usd
CY2021	us-gaap	Depreciation Depreciation	17627	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	345925	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	389396	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	5793	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	9136	usd
CY2022Q4	przo	Governmental Institution GovernmentalInstitution	120126	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0"><b>Y. Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. </span>The Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying balance sheets exceed federally insured limits. The Company places its cash and cash equivalents with two financial institutions with high-quality credit ratings in Israel and has not experienced any losses in such accounts.</p>
CY2023Q4	przo	Governmental Institution GovernmentalInstitution	233501	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	349632	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	59415	usd
CY2023Q4	przo	Other Current Assets OtherCurrentAssets	68427	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	651560	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	179541	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	261192	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	284028	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3276	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	20791	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	264468	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	304823	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	33000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	12000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	50000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	45891	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	47425	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	50103	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y1M30D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M30D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M30D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8126	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8126	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	583	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7543	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1514928	usd
CY2023	przo	Initial Public Offering Price Discounted Percentage InitialPublicOfferingPriceDiscountedPercentage	0.25	pure
CY2023	przo	Percentage Of Discount On Purchase Amount PercentageOfDiscountOnPurchaseAmount	0.20	pure
CY2023	przo	Percentage Of Discount On Investment Percentage PercentageOfDiscountOnInvestmentPercentage	0.20	pure
CY2023Q4	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	3.313	aud
CY2023Q4	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	2.3	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1514928	usd
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.25	pure
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	504976	shares
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	195509	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	137597	usd
CY2023Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	201762	usd
CY2022Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	185002	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	5793	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	9136	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	287797	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	442912	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	690861	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	774647	usd
CY2023Q4	przo	Equity Instruments Amount EquityInstrumentsAmount	975811	usd
CY2023Q4	przo	Fair Value Initial Measurement FairValueInitialMeasurement	1287173	usd
CY2023	przo	Equity Instruments Amount EquityInstrumentsAmount	3795338	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3066656	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	przo	Ordinary Per Share OrdinaryPerShare	0.00555
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 26, 2022, the shareholders of the Company approved a 1-for-2 reverse stock split of the Company’s Ordinary Shares, pursuant to which holders of Ordinary Shares received one Ordinary Share, par value NIS 0.02, for every two ordinary shares, par value NIS 0.01, held before the reverse stock split.
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	610156	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	243984	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	366172	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.275
CY2023Q3	przo	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisablePeriod	P5Y
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	212199	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	366172	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.275
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	366172	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.275
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y8M12D
CY2023	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	197384	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q4	przo	Fair Value Initial Measurement FairValueInitialMeasurement	1287173	usd
CY2023	przo	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	277600	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1564773	usd
CY2022Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	4200000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	745000	usd
	us-gaap	Proceeds From Loans ProceedsFromLoans	745000	usd
CY2023Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	7073	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	10396	usd
CY2023Q3	przo	Line Of Credit Facility Aggregate Initial Amount LineOfCreditFacilityAggregateInitialAmount	745000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.23	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3612947	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2693459	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	145249	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	135367	usd
CY2023Q4	przo	Deferred Tax Assets Provision For Warranty DeferredTaxAssetsProvisionForWarranty	-1332	usd
CY2022Q4	przo	Deferred Tax Assets Provision For Warranty DeferredTaxAssetsProvisionForWarranty	-2101	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	17459	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	15799	usd
CY2023Q4	przo	Deferred Tax Assets Issuance Cost DeferredTaxAssetsIssuanceCost	81010	usd
CY2022Q4	przo	Deferred Tax Assets Issuance Cost DeferredTaxAssetsIssuanceCost	86464	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3857998	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2933190	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3857998	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2933190	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	15700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	12700000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	0	usd
CY2023	przo	Aggregate Rental Payment AggregateRentalPayment	71000	ils
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y
CY2023	przo	Bank Guarantee Amount BankGuaranteeAmount	248000	ils
CY2023Q4	przo	Deferred Prospective Initial Public Offering Cost DeferredProspectiveInitialPublicOfferingCost		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense		usd
CY2022	przo	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2021	przo	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	przo	Issuance Expenses Attributable To Derivative Warrant Liability IssuanceExpensesAttributableToDerivativeWarrantLiability		usd
CY2021	przo	Issuance Expenses Attributable To Derivative Warrant Liability IssuanceExpensesAttributableToDerivativeWarrantLiability		usd
CY2021	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.77
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.71
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3349071	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4891071	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	359743	shares
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2021	przo	Interest Expenses With Respect To Funding From Related Party InterestExpensesWithRespectToFundingFromRelatedParty		usd
CY2022	przo	Change In Fair Value Of Convertible Loan ChangeInFairValueOfConvertibleLoan		usd
CY2021	przo	Change In Fair Value Of Convertible Loan ChangeInFairValueOfConvertibleLoan		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	przo	Issuance Expenses Attributable To Derivative Warrant Liabilities IssuanceExpensesAttributableToDerivativeWarrantLiabilities		usd
CY2021	przo	Issuance Expenses Attributable To Derivative Warrant Liabilities IssuanceExpensesAttributableToDerivativeWarrantLiabilities		usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2023	przo	Increase Decrease In Deferred Prospective Initial Public Offering Cost IncreaseDecreaseInDeferredProspectiveInitialPublicOfferingCost		usd
CY2021	przo	Increase Decrease In Deferred Prospective Initial Public Offering Cost IncreaseDecreaseInDeferredProspectiveInitialPublicOfferingCost		usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet		usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet		usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
CY2022	przo	Issuance Of Ordinary Shares Prefunded Warrants And Warrants In Private Placement Net Of Issuan IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsInPrivatePlacementNetOfIssuan		usd
CY2021	przo	Issuance Of Ordinary Shares Prefunded Warrants And Warrants In Private Placement Net Of Issuan IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsInPrivatePlacementNetOfIssuan		usd
CY2021	przo	Proceeds From Receipt Of Loan Related Party ProceedsFromReceiptOfLoanRelatedParty		usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt		usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	przo	Cash Received From Interest CashReceivedFromInterest		usd
CY2021	przo	Cash Received From Interest CashReceivedFromInterest		usd
CY2023	przo	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
CY2021	przo	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
CY2023	przo	Conversion Of The Former Parent Companys Debt Into Ordinary Shares ConversionOfTheFormerParentCompanysDebtIntoOrdinaryShares		usd
CY2021	przo	Conversion Of The Former Parent Companys Debt Into Ordinary Shares ConversionOfTheFormerParentCompanysDebtIntoOrdinaryShares		usd
CY2021	przo	Benefit To The Company By An Equity Holder With Respect To Funding Transactions BenefitToTheCompanyByAnEquityHolderWithRespectToFundingTransactions		usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2021	przo	Stock Based Compensation Included As Issuance Costs StockBasedCompensationIncludedAsIssuanceCosts		usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Open Tax Year OpenTaxYear	2017
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001916241

Files In Submission

Name	View Source	Status
0001213900-24-024822-index-headers.html	Edgar Link	pending
0001213900-24-024822-index.html	Edgar Link	pending
0001213900-24-024822.txt	Edgar Link	pending
0001213900-24-024822-xbrl.zip	Edgar Link	pending
ea0201876-20f_parazero.htm	Edgar Link	pending
ea020187601ex12-1_parazero.htm	Edgar Link	pending
ea020187601ex12-2_parazero.htm	Edgar Link	pending
ea020187601ex13-1_parazero.htm	Edgar Link	pending
ea020187601ex13-2_parazero.htm	Edgar Link	pending
ea020187601ex2-1_parazero.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
przo-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
przo-20231231_cal.xml	Edgar Link	unprocessable
przo-20231231_def.xml	Edgar Link	unprocessable
przo-20231231_pre.xml	Edgar Link	unprocessable
ea0201876-20f_parazero_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
przo-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRZO
ParaZero Technologies Ltd. Stock $przo

2023 Q4 Form 20-F Financial Statement

#000121390024024822 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRZO ParaZero Technologies Ltd. Stock $przo

2023 Q4 Form 20-F Financial Statement

#000121390024024822 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRZO
ParaZero Technologies Ltd. Stock $przo